Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)
This study is testing a targeted cancer medicine called T-DXd to see how well it reaches brain tumors and helps treat them. Researchers want to find out if this medicine can effectively fight cancers that have spread to the brain or started there.
You may be able to join if you are 18 or older, have a brain tumor, and are already scheduled for brain surgery to remove it or take a tissue sample. Your tumor must also test positive for a specific protein called HER2.
You will receive the study medication before your scheduled brain surgery so researchers can check how much of the drug reaches the tumor tissue. You will also have safety checks like MRI scans and follow-up visits to monitor your health.
The study is currently recruiting participants and takes place in New York, New York, United States.
- 1Tests a targeted cancer medication called T-DXd for brain tumors.
- 2Requires participants to be scheduled for brain surgery.
- 3Currently recruiting patients in New York.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.